Pfizer Inc. (NYSE:PFE) Shares Sold by Oppenheimer & Close LLC
Pfizer Inc. (NYSE:PFE) Shares Sold by Oppenheimer & Close LLC
Oppenheimer & Close LLC lowered its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 5.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 142,581 shares of the biopharmaceutical company's stock after selling 7,445 shares during the quarter. Pfizer accounts for approximately 8.5% of Oppenheimer & Close LLC's holdings, making the stock its 2nd biggest holding. Oppenheimer & Close LLC's holdings in Pfizer were worth $7,475,000 at the end of the most recent quarter.
Oppenheimer&Close LLC在提交给美国证券交易委员会的最新Form 13F文件中称，该公司在第二季度将其在辉瑞(纽约证券交易所代码：PFE-GET评级)的持股比例下调了5.0%。该机构投资者在本季度出售了7,445股后，持有这家生物制药公司的142,581股股票。辉瑞约占Oppenheimer&Close LLC所持股份的8.5%，使其成为其第二大持股。截至最近一个季度末，Oppenheimer&Close LLC持有的辉瑞股份价值7,475,000美元。
A number of other hedge funds have also made changes to their positions in PFE. Ullmann Wealth Partners Group LLC increased its position in Pfizer by 6.2% during the 1st quarter. Ullmann Wealth Partners Group LLC now owns 5,759 shares of the biopharmaceutical company's stock worth $298,000 after purchasing an additional 335 shares in the last quarter. Red Door Wealth Management LLC increased its position in Pfizer by 8.6% during the 1st quarter. Red Door Wealth Management LLC now owns 109,620 shares of the biopharmaceutical company's stock worth $5,675,000 after purchasing an additional 8,694 shares in the last quarter. Capital City Trust Co. FL increased its position in Pfizer by 49.9% during the 1st quarter. Capital City Trust Co. FL now owns 8,464 shares of the biopharmaceutical company's stock worth $438,000 after purchasing an additional 2,816 shares in the last quarter. Colonial River Wealth Management LLC increased its position in Pfizer by 52.3% during the 1st quarter. Colonial River Wealth Management LLC now owns 20,988 shares of the biopharmaceutical company's stock worth $1,087,000 after purchasing an additional 7,206 shares in the last quarter. Finally, Annex Advisory Services LLC increased its position in Pfizer by 23.6% during the 1st quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company's stock worth $532,000 after purchasing an additional 1,966 shares in the last quarter. Hedge funds and other institutional investors own 67.90% of the company's stock.
其他一些对冲基金也调整了他们在PFE的仓位。Ullmann Wealth Partners Group LLC在第一季度将其在辉瑞的头寸增加了6.2%。Ullmann Wealth Partners Group LLC现在持有这家生物制药公司5759股股票，价值29.8万美元，上个季度又购买了335股。红门财富管理有限责任公司第一季度将其在辉瑞的头寸增加了8.6%。Red Door Wealth Management LLC现在持有这家生物制药公司109,620股股票，价值5,675,000美元，上个季度又购买了8,694股。第一季度Capital City Trust Co.FL将其在辉瑞的持仓增加了49.9%。Capital City Trust Co.FL现在持有这家生物制药公司8,464股股票，价值438,000美元，上个季度又购买了2,816股。殖民地河流财富管理有限责任公司在第一季度将其在辉瑞的头寸增加了52.3%。殖民地河流财富管理有限责任公司现在拥有20,988股生物制药公司的股票，价值108.7万美元，在上个季度又购买了7206股。最后，附件咨询服务有限责任公司在第一季度将其在辉瑞公司的头寸增加了23.6%。在上个季度又购买了1,966股后，附件咨询服务公司现在拥有这家生物制药公司10,279股股票，价值532,000美元。对冲基金和其他机构投资者持有该公司67.90%的股票。
Pfizer Stock Performance
辉瑞股票表现
Pfizer stock opened at $44.08 on Friday. The stock's 50 day moving average price is $48.24 and its 200 day moving average price is $50.32. The firm has a market capitalization of $247.39 billion, a PE ratio of 8.63, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71.
辉瑞股价周五开盘报44.08美元。该股的50日移动均线价格为48.24美元，200日移动均线价格为50.32美元。该公司市值为2473.9亿美元，市盈率为8.63倍，市盈率为0.54倍，贝塔系数为0.70倍。该公司的债务权益比率为0.39，速动比率为1.20，流动比率为1.42。辉瑞公司股价一年来最低为40.94美元，一年最高为61.71美元。
Pfizer Dividend Announcement
辉瑞宣布派息
The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.63%. The ex-dividend date is Thursday, November 3rd. Pfizer's dividend payout ratio (DPR) is presently 31.31%.
该公司最近还宣布了季度股息，将于12月5日(星期一)支付。11月4日(星期五)登记在册的投资者将获得每股0.40美元的股息。这意味着1.60美元的年化股息和3.63%的收益率。除息日期为11月3日星期四。辉瑞的股息支付率(DPR)目前为31.31%。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of analysts recently commented on the company. SVB Leerink dropped their price objective on Pfizer from $55.00 to $53.00 and set a "market perform" rating for the company in a research report on Friday, July 29th. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a report on Tuesday, June 28th. The Goldman Sachs Group set a $50.00 price target on Pfizer in a report on Thursday, September 1st. Berenberg Bank set a $44.00 price target on Pfizer in a report on Wednesday, September 14th. Finally, Barclays set a $50.00 price target on Pfizer in a report on Thursday, September 1st. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.00.
一些分析师最近对该公司发表了评论。SVB Leerink在7月29日星期五的一份研究报告中将辉瑞的目标价从55.00美元下调至53.00美元，并为该公司设定了“市场表现”评级。摩根大通在6月28日周二的一份报告中为辉瑞设定了57.00美元的目标价。高盛在9月1日星期四的一份报告中为辉瑞设定了50美元的目标价。贝伦伯格银行在9月14日星期三的一份报告中为辉瑞设定了44.00美元的目标价。最后，巴克莱在9月1日周四的一份报告中为辉瑞设定了50.00美元的目标价。9名股票研究分析师对该股的评级为持有，10名分析师给出了买入评级，一名分析师给出了强烈的买入评级。根据MarketBeat的数据，该公司目前的共识评级为“适度买入”，共识目标价为57.00美元。
About Pfizer
关于辉瑞公司
(Get Rating)
(获取评级)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
辉瑞在全球发现、开发、制造、营销、分销和销售生物制药产品。该公司在不同的治疗领域提供药物和疫苗，包括Premarin系列和Eiquis品牌的心血管代谢和妇女健康；Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物制品、小分子、免疫疗法和生物仿制药；舒必乐、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的无菌注射和抗感染药物以及口服新冠肺炎治疗。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- 免费获取StockNews.com关于辉瑞的研究报告
- 华尔街对Datadog的热情会带来巨大的收益吗？
- MarketBeat：回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性？
- 好市多盈利后价格疲软是买入的好时机吗？
- 需要关注的2只半导体类股走势逆转
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
想看看其他对冲基金持有PFE吗？访问HoldingsChannel.com获取辉瑞的最新13F备案文件和内幕交易。
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
接受辉瑞日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对辉瑞及相关公司评级的每日简明摘要。
译文内容由第三方软件翻译。